JMP Securities Downgrades Intra-Cellular Therapies (ITCI) to Market Perform

September 29, 2016 6:52 AM EDT
Get Alerts ITCI Hot Sheet
Price: $12.83 -1.76%

Rating Summary:
    5 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 27 | New: 7
Trade ITCI Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

JMP Securities downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Market Outperform to Market Perform and removed its price target (prior $55.00).

For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.

Shares of Intra-Cellular Therapies closed at $42.35 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

The Children's Investment Fund (TCI), JMP Securities

Add Your Comment